Product containing glucagon-like peptide 1 receptor agonist (product)

FDA Grants Wegovy 3rd Indication: First GLP-1 Approved for MASH with Moderate-to-Advanced Liver Scarring

3 weeks ago talkbio0Tagged Accelerated, Approved, Fibrosis, Liver, MASH, noncirrhotic, Nordisk, Product containing glucagon-like peptide 1 receptor agonist (product), semaglutide, United States Food and Drug Administration, Wegovy

Wegovy; FDA approval; MASH; semaglutide; GLP-1 receptor agonist; liver fibrosis; Novo Nordisk; ESSENCE trial; noncirrhotic; accelerated approval

Madrigal Pharmaceuticals Inks up to $2B Deal with CSPC for Preclinical Oral GLP-1, Plans Combination with Rezdiffra for MASH

1 month ago talkbio0Tagged Combined Modality Therapy, global license agreement, GZMH gene, Madrigal Pharmaceuticals, MASH, milestone payments, oral small molecule, Pharmaceutical Group, preclinical drug, Product containing glucagon-like peptide 1 receptor agonist (product), Rezdiffra

Madrigal Pharmaceuticals; CSPC Pharmaceutical Group; GLP-1 receptor agonist; SYH2086; Rezdiffra; MASH; oral small molecule; preclinical drug; global license agreement; combination therapy; milestone payments

Ascletis’ Oral GLP-1 Drug Shows Promising Early Results in Obesity Treatment, Rivaling Roche’s Candidate

7 months ago talkbio0Tagged ASC30, Ascletis, Clinical Trials, CT-996, Obesity, Oral cavity, Pharma, Pharmaceutical competition, Product containing glucagon-like peptide 1 receptor agonist (product), Roche (company)

Ascletis Pharma, obesity treatment, oral GLP-1 receptor agonist, ASC30, weight loss, clinical trials, Roche, CT-996, pharmaceutical competition

Metsera Emerges with $290M to Rival Obesity Pharmaceutical Giants Lilly and Novo

1 year ago talkbio0Tagged Eli Lilly, Metsera, Novo, Obesity, Phase I injectable, Product containing glucagon-like peptide 1 receptor agonist (product)

Metsera, $290M funding, Obesity treatment, Challenge Lilly and Novo, GLP-1 receptor agonist (Phase I injectable)